Inhibikase Therapeutics (IKT) Revenue & Revenue Breakdown
Inhibikase Therapeutics Revenue Highlights
0
Latest Revenue (Q)
$26.27K
Inhibikase Therapeutics Revenue by Period
Inhibikase Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $260.50K | 111.03% |
| 2022-12-31 | $123.44K | -96.02% |
| 2021-12-31 | $3.10M | 343.92% |
| 2020-12-31 | $698.47K | -37.79% |
| 2019-12-31 | $1.12M | -72.22% |
| 2018-12-31 | $4.04M | 96.07% |
| 2017-12-31 | $2.06M | 113.04% |
| 2016-12-31 | $967.39K | - |
Inhibikase Therapeutics generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Inhibikase Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $26.27K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2023-09-30 | $79.57K | -31.65% |
| 2023-06-30 | $116.41K | 80.42% |
| 2023-03-31 | $64.52K | -47.73% |
| 2022-12-31 | $123.44K | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $6.55K | -85.77% |
| 2022-03-31 | $46.03K | 2267.85% |
| 2021-12-31 | $1.94K | -99.41% |
| 2021-09-30 | $328.46K | -75.90% |
| 2021-06-30 | $1.36M | -3.14% |
| 2021-03-31 | $1.41M | 101.46% |
| 2020-12-31 | $698.47K | 1753.68% |
| 2020-09-30 | $37.68K | -82.84% |
| 2020-06-30 | $219.59K | -18.91% |
| 2020-03-31 | $270.79K | 12.70% |
| 2019-12-31 | $240.28K | 93.10% |
| 2019-09-30 | $124.43K | -25.46% |
| 2019-06-30 | $166.93K | -71.76% |
| 2019-03-31 | $591.10K | -56.05% |
| 2018-12-31 | $1.35M | 94.60% |
| 2018-03-31 | $691.20K | -13.32% |
| 2017-12-31 | $797.40K | 222.34% |
| 2017-03-31 | $247.38K | - |
Inhibikase Therapeutics generated $26.27K in revenue during Q4 2024, up 100.00% compared to the previous quarter, and up 33.02% compared to the same period a year ago.